(NASDAQ: PBYI) Puma Biotechnology's forecast annual revenue growth rate of -1.6% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.4%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.27%.
Puma Biotechnology's revenue in 2026 is $231,244,000.On average, 3 Wall Street analysts forecast PBYI's revenue for 2026 to be $11,688,847,745, with the lowest PBYI revenue forecast at $11,230,461,559, and the highest PBYI revenue forecast at $12,032,637,385. On average, 3 Wall Street analysts forecast PBYI's revenue for 2027 to be $11,530,890,343, with the lowest PBYI revenue forecast at $11,078,698,565, and the highest PBYI revenue forecast at $11,870,034,177.
In 2028, PBYI is forecast to generate $11,372,932,941 in revenue, with the lowest revenue forecast at $10,926,935,571 and the highest revenue forecast at $11,707,430,969.